Integra LifeSciences Holdings Co. (NASDAQ:IART) Shares Sold by Kestrel Investment Management Corp

Kestrel Investment Management Corp cut its holdings in Integra LifeSciences Holdings Co. (NASDAQ:IART) by 18.3% in the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 100,050 shares of the life sciences company’s stock after selling 22,400 shares during the period. Integra LifeSciences accounts for about 2.9% of Kestrel Investment Management Corp’s holdings, making the stock its 15th biggest position. Kestrel Investment Management Corp owned 0.13% of Integra LifeSciences worth $4,357,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of the business. Itau Unibanco Holding S.A. increased its holdings in shares of Integra LifeSciences by 469.5% during the 2nd quarter. Itau Unibanco Holding S.A. now owns 746 shares of the life sciences company’s stock worth $31,000 after buying an additional 615 shares during the last quarter. Gladius Capital Management LP purchased a new position in Integra LifeSciences in the 3rd quarter valued at about $47,000. Covestor Ltd boosted its position in Integra LifeSciences by 82.5% in the 3rd quarter. Covestor Ltd now owns 2,037 shares of the life sciences company’s stock valued at $78,000 after buying an additional 921 shares during the last quarter. Coppell Advisory Solutions LLC purchased a new position in Integra LifeSciences in the 2nd quarter valued at about $84,000. Finally, Captrust Financial Advisors boosted its position in Integra LifeSciences by 95.0% in the 1st quarter. Captrust Financial Advisors now owns 2,003 shares of the life sciences company’s stock valued at $129,000 after buying an additional 976 shares during the last quarter. 84.78% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities analysts have weighed in on the stock. Truist Financial decreased their price objective on shares of Integra LifeSciences from $46.00 to $41.00 and set a “hold” rating for the company in a research report on Friday, March 1st. Citigroup raised shares of Integra LifeSciences from a “sell” rating to a “neutral” rating and set a $38.00 price objective for the company in a research report on Wednesday, April 3rd. JMP Securities decreased their price objective on shares of Integra LifeSciences from $55.00 to $49.00 and set a “market outperform” rating for the company in a research report on Thursday, February 29th. Finally, StockNews.com cut shares of Integra LifeSciences from a “buy” rating to a “hold” rating in a research report on Friday, April 5th. Two equities research analysts have rated the stock with a sell rating, four have issued a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $44.89.

Integra LifeSciences Stock Performance

IART traded down $2.95 on Friday, hitting $28.68. 2,916,232 shares of the company’s stock were exchanged, compared to its average volume of 675,664. The firm has a market cap of $2.25 billion, a PE ratio of 34.55, a P/E/G ratio of 0.96 and a beta of 1.12. Integra LifeSciences Holdings Co. has a twelve month low of $27.85 and a twelve month high of $59.10. The stock has a fifty day moving average of $36.85 and a two-hundred day moving average of $39.08. The company has a current ratio of 3.45, a quick ratio of 2.18 and a debt-to-equity ratio of 0.94.

Integra LifeSciences (NASDAQ:IART) last released its quarterly earnings data on Wednesday, February 28th. The life sciences company reported $0.89 earnings per share for the quarter, missing the consensus estimate of $0.90 by ($0.01). The business had revenue of $397.00 million for the quarter, compared to analyst estimates of $399.30 million. Integra LifeSciences had a return on equity of 15.19% and a net margin of 4.39%. Integra LifeSciences’s revenue was down .3% compared to the same quarter last year. During the same quarter last year, the company earned $0.94 EPS. On average, research analysts anticipate that Integra LifeSciences Holdings Co. will post 3.19 earnings per share for the current fiscal year.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.